Quantified terminal tumor weights confirmed that the antitumor effects of two ICAM1 ADCs are significantly more potent than Cis (44.32%) at the same dose with their tumor inhibition rates determined as 85.80% (I-MMAE) and 91.38% (I-DXd), noting that ICAM1 antibody alone had no obvious inhibitory effect on the cervical tumor (Fig. 2f). Here, ICAM1 is linked to uterine cervix neoplasm.